NASDAQ:CSII - Cardiovascular Systems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.14
  • Forecasted Upside: 26.63 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$35.65
▼ -0.51 (-1.41%)
1 month | 3 months | 12 months
Get New Cardiovascular Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSII

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.14
▲ +26.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cardiovascular Systems in the last 3 months. The average price target is $45.14, with a high forecast of $48.00 and a low forecast of $40.00. The average price target represents a 26.63% upside from the last price of $35.65.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Cardiovascular Systems.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/8/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2020Needham & Company LLCReiterated RatingBuy$44.00High
i
8/12/2020AegisBoost Price TargetBuy$45.00 ➝ $47.00Low
i
Rating by N. Weinstein at Aegis
8/5/2020SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $45.00Medium
i
7/22/2020Northland SecuritiesInitiated CoverageOutperform$40.00Medium
i
7/17/2020BarclaysInitiated CoverageOverweight$45.00High
i
6/19/2020AegisInitiated CoverageBuy$45.00Medium
i
Rating by N. Weinstein at Aegis
6/11/2020Needham & Company LLCUpgradeHold ➝ Buy$44.00High
i
5/6/2020Needham & Company LLCReiterated RatingHoldHigh
i
5/6/2020Lake Street CapitalLower Price TargetBuy$54.00 ➝ $48.00High
i
4/28/2020SVB LeerinkLower Price TargetOutperform$60.00 ➝ $50.00High
i
4/19/2020OppenheimerInitiated CoverageOutperform$47.00Low
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
4/6/2020OppenheimerInitiated CoverageOutperform$47.00Low
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
4/3/2020Lake Street CapitalLower Price TargetBuy$60.00 ➝ $54.00High
i
10/17/2019GuggenheimInitiated CoverageBuy$58.00High
i
8/7/2019Needham & Company LLCReiterated RatingHoldLow
i
Rating by Michael Matson at Needham & Company LLC
8/7/2019Lake Street CapitalBoost Price TargetBuy$50.00 ➝ $60.00High
i
7/16/2019Stifel NicolausDowngradeBuy ➝ Hold$41.00 ➝ $45.00Low
i
5/2/2019Needham & Company LLCReiterated RatingHoldHigh
i
4/11/2019Bank of AmericaDowngradeBuy ➝ Underperform$42.00High
i
10/31/2018Needham & Company LLCReiterated RatingHoldHigh
i
8/22/2018Stifel NicolausInitiated CoverageBuy$45.00Medium
i
8/1/2018Lake Street CapitalReiterated RatingBuy$50.00Medium
i
6/27/2018Bank of AmericaUpgradeUnderperform ➝ BuyHigh
i
5/3/2018Needham & Company LLCReiterated RatingHoldHigh
i
2/8/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$31.00 ➝ $30.00High
i
12/21/2017William BlairReiterated RatingMarket PerformLow
i
Rating by Margaret Kaczor at William Blair
12/15/2017Needham & Company LLCDowngradeBuy ➝ Hold$33.11 ➝ $23.00High
i
12/4/2017Raymond JamesReiterated RatingHoldLow
i
10/26/2017Needham & Company LLCReiterated RatingBuy$37.00 ➝ $36.00N/A
i
10/12/2017Needham & Company LLCReiterated RatingBuy$37.00N/A
i
9/22/2017Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformLow
i
9/21/2017CitigroupInitiated CoverageMarket PerformLow
i
7/14/2017Needham & Company LLCReiterated RatingBuy$32.00 ➝ $37.00High
i
6/21/2017Bank of AmericaDowngradeNeutral ➝ UnderperformLow
i
4/18/2017Needham & Company LLCReiterated RatingBuy$32.00Low
i
1/30/2017Lake Street CapitalInitiated CoverageBuy$40.00N/A
i
1/26/2017Needham & Company LLCBoost Price TargetBuy$27.00 ➝ $32.00N/A
i
11/15/2016SVB LeerinkReiterated RatingOutperform$30.00N/A
i
10/27/2016Feltl & Co.UpgradeBuy ➝ Strong-Buy$30.00N/A
i
Rating by B. Haynor at Feltl & Co.
10/7/2016JMP SecuritiesInitiated CoverageOutperform$35.00N/A
i
8/22/2016SVB LeerinkUpgradeMarket Perform ➝ Outperform$30.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
8/4/2016Needham & Company LLCBoost Price TargetBuy$23.00 ➝ $27.00N/A
i
Rating by Michael Matson at Needham & Company LLC
8/4/2016Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
i
6/29/2016Needham & Company LLCReiterated RatingBuy$20.00 ➝ $23.00N/A
i
Rating by Michael Matson at Needham & Company LLC
5/7/2016SVB LeerinkReiterated RatingMarket Perform$13.00 ➝ $15.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/5/2016Needham & Company LLCBoost Price TargetBuy$16.00 ➝ $20.00N/A
i
Rating by Michael Matson at Needham & Company LLC
4/1/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
4/1/2016Needham & Company LLCUpgradeUnderperform ➝ Buy$16.00N/A
i
Rating by Michael Matson at Needham & Company LLC
1/22/2016SVB LeerinkReiterated RatingHold$17.00 ➝ $13.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
1/22/2016Needham & Company LLCDowngradeBuy ➝ UnderperformN/A
i
Rating by Michael Matson at Needham & Company LLC
12/23/2015Northcoast ResearchInitiated CoverageBuy$18.00N/A
i
Rating by E. Shoger at Northcoast Research
11/5/2015Needham & Company LLCBoost Price TargetBuy$18.00 ➝ $19.00N/A
i
Rating by Michael Matson at Needham & Company LLC
(Data available from 10/31/2015 forward)
Cardiovascular Systems logo
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.
Read More

Today's Range

Now: $35.65
$35.26
$36.66

50 Day Range

MA: $36.87
$33.60
$39.35

52 Week Range

Now: $35.65
$26.00
$55.22

Volume

221,585 shs

Average Volume

241,231 shs

Market Capitalization

$1.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11